Technical Analysis for VCEL - Vericel Corporation
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Gapped Down | Weakness | 1.32% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -0.13% | |
| NR7 | Range Contraction | -0.13% | |
| Narrow Range Bar | Range Contraction | -0.13% | |
| Inside Day | Range Contraction | -0.13% | |
| Oversold Stochastic | Weakness | -0.80% | |
| New Downtrend | Bearish | 1.48% | |
| Slingshot Bearish | Bearish Swing Setup | 1.48% | |
| Oversold Stochastic | Weakness | 1.48% | |
| Doji - Bullish? | Reversal | 5.28% |
| Alert | Time |
|---|---|
| 10 DMA Resistance | about 15 hours ago |
| Rose Above 10 DMA | about 16 hours ago |
| Up 1% | about 16 hours ago |
| 60 Minute Opening Range Breakout | about 17 hours ago |
| Rose Above Previous Day's High | about 17 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/08/2024
Vericel Corporation Description
Vericel Corporation, a commercial-stage biopharmaceutical company, focuses on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets two autologous cell therapy products in the United States, including Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee; and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area. The company is also developing MACI, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee; and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company, formerly known as Aastrom Biosciences, Inc., was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Stem Cell Cell Therapy Heart Failure Knee Burns Cardiomyopathy Myopathy Cartilage Osteochondritis Dissecans Severe Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 53.05 |
| 52 Week Low | 30.18 |
| Average Volume | 446,201 |
| 200-Day Moving Average | 38.78 |
| 50-Day Moving Average | 47.33 |
| 20-Day Moving Average | 48.14 |
| 10-Day Moving Average | 45.95 |
| Average True Range | 1.65 |
| RSI (14) | 45.36 |
| ADX | 24.8 |
| +DI | 20.57 |
| -DI | 32.60 |
| Chandelier Exit (Long, 3 ATRs) | 48.10 |
| Chandelier Exit (Short, 3 ATRs) | 47.32 |
| Upper Bollinger Bands | 53.34 |
| Lower Bollinger Band | 42.94 |
| Percent B (%b) | 0.3 |
| BandWidth | 21.61 |
| MACD Line | -0.60 |
| MACD Signal Line | -0.22 |
| MACD Histogram | -0.3831 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 47.48 | ||||
| Resistance 3 (R3) | 47.42 | 46.88 | 47.24 | ||
| Resistance 2 (R2) | 46.88 | 46.52 | 46.91 | 47.16 | |
| Resistance 1 (R1) | 46.47 | 46.30 | 46.68 | 46.53 | 47.08 |
| Pivot Point | 45.93 | 45.93 | 46.04 | 45.96 | 45.93 |
| Support 1 (S1) | 45.52 | 45.57 | 45.73 | 45.58 | 45.02 |
| Support 2 (S2) | 44.98 | 45.35 | 45.01 | 44.94 | |
| Support 3 (S3) | 44.57 | 44.98 | 44.86 | ||
| Support 4 (S4) | 44.63 |
